What Оксибрал СР Treats: Main Uses and Benefits

Оксибрал СР is considered relevant in the management of chronic conditions characterized by insufficient blood flow and circulation within the brain, such as cerebrovascular insufficiency and certain presentations of vascular dementia. The active compound is relevant for easing symptoms related to cerebral circulatory impairment and general cognitive impairments. This therapeutic application provides support for neurological function and may help to reduce the overall symptom burden associated with long-standing circulatory deficits, particularly in older adults.

The medication helps to address symptom clusters that may become disruptive, including difficulties with concentration, diminished attention span, mild memory impairment, persistent dizziness (vertigo), and chronic ringing in the ears (tinnitus). By supporting function in these domains, it offers symptomatic relief that helps patients cope more steadily with these challenges.

“The medication is applied in scenarios involving a combination of cognitive symptoms and physical disturbances related to chronic cerebral circulatory issues.”

Quick Fact	Symptom Domain Supported
Cognitive Support	Difficulty with concentration and memory deficits.
Neuro-Sensory Relief	Chronic dizziness (vertigo) and tinnitus.
Symptom Categories Addressed	Symptoms of chronic cerebrovascular insufficiency.

The official regulatory documents for Оксибрал СР (Vincamine) define eligibility by establishing both absolute contraindications and conditional restrictions for specific patient populations. The medicine is primarily intended for use in adults and the geriatric population for chronic conditions.

Contraindicated Populations

Use is strictly prohibited for individuals with known hypersensitivity to Vincamine or any excipient. Regulatory labeling also classifies patients with acute cerebral hemorrhage or conditions resulting in increased intracranial pressure (such as certain tumors) as non-eligible.

Age-Related Eligibility and Restrictions

Use in the pediatric population (children and adolescents under 18 years) is officially not recommended or contraindicated, as safety and efficacy have not been formally established. The medicine is also officially not recommended for use during pregnancy and lactation.

Organ Function Limitations

Eligibility is subject to limitations in cases of severe organ dysfunction. Use is classified as restricted or requires special caution in individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment due to the drug’s potential for altered metabolism and clearance.

The interaction profile of Оксибрал СР (Oksibral SR), based on its Cinnarizine component, is primarily characterized by the risk of additive effects with other medicines that act on the nervous system. These interactions are typically managed by exercising caution and close monitoring.

Documented Interacting Substance Categories

Interacting Substance Category	Potential Interaction Mechanism and Effect
CNS Depressants & Alcohol	Additive central nervous system (CNS) depression, significantly potentiating effects such as drowsiness, sedation, and impaired alertness. This includes Alcohol, Barbiturates, Hypnotics, Narcotic Analgesics, and Tranquilizers.
Antidepressants	Certain classes, specifically Tricyclic Antidepressants, may potentiate the sedative effects.
Antimuscarinic Drugs	Risk of additive anticholinergic actions, which may worsen side effects like dry mouth or urinary retention.
Ototoxic Drugs	Cinnarizine may mask the warning signs of damage caused by ototoxic medicines (e.g., Aminoglycoside Antibiotics) due to its effects on the vestibular system.

The overall regulatory view classifies these as use with caution combinations, emphasizing the procedural need for monitoring to manage potential somnolence or masking of ototoxicity. No specific drug spacing or timing requirements are universally documented in the official labeling, but patients must be aware of the increased risk of drowsiness when combining with any substance that causes central depression.

Influence on Cerebral Vascular Tone

The molecule acts at the molecular level by blocking specific voltage-gated sodium channels ( Na^+ channels) located in the smooth muscle walls of cerebral blood vessels. This action leads to the relaxation of cerebral arteries, resulting in an increase in regional cerebral blood flow ( CBF) that is most prominent in regions with lower existing blood supply. This change in hemodynamics facilitates the transfer of oxygen ( O2) and glucose to neural tissue.

Regulation of Neuronal Metabolism and Cellular Integrity

Beyond its vascular effects, Vincamine engages intracellular mechanisms to influence nerve cell function. It affects the utilization of O2 and glucose, thereby influencing neuronal metabolic processes. Simultaneously, the drug modulates protective signaling pathways, such as those governing oxidative stress ( Nrf2) and cellular apoptosis ( NF-kappa B), which contributes to maintaining the functional state of neurons during metabolic stress.

The Sustained-Release (SR) formulation ensures a continuous, stable concentration necessary to maintain the long-term engagement of the vascular and metabolic targets.

The sole approved administration route for Оксибрал СР is oral ingestion, consistent with its designated formulation as a Sustained-Release (SR) capsule. The medicine contains the active substance Vincamine, a compound recognized for its properties as an indole alkaloid. The standard labeled dosing for adults is 30 mg of the active ingredient per administration.

The official administration guidelines specify that this medicine be taken twice daily (BID), typically with one capsule in the morning and a second capsule approximately twelve hours later. This twice-daily frequency is essential to maintain the stable, continuous release pattern of the SR form, ensuring consistency as specified in pharmaceutical product information. The duration of the therapeutic course is not predefined by a fixed cycle but is determined individually by the prescribing healthcare professional.

For specific populations, the official prescribing information states that the standard adult dose is utilized for older adults (geriatric patients), without requiring specialized dosage adjustments. Since the medicine is a Sustained-Release capsule, the procedural structure requires swallowing the capsule whole and intact, as breaking or chewing the capsule would compromise the intended function. No explicit instructions are uniformly provided in official prescribing documents regarding administration with or without food.

Research Evidence / Overview of Studies

Research Regarding Migraine Frequency and Severity

Research has examined whether the study compound was associated with differences in the frequency and severity of migraine attacks.

One large-scale randomized control trial reported that participants receiving the active compound reported a change in the number of monthly migraine days compared to placebo during the study period.

The trial reported that the study results were also noted across various participant subgroups, suggesting that research evaluated the compound's use in diverse populations.

Quality of Life and Symptom Assessment

Studies have also explored whether patient-reported quality of life (QoL) was measured. The compound was studied under a daily administration schedule. Information regarding changes to the administration schedule was not the primary focus of this research.

Research assessed whether the compound was associated with a measured difference in reported pain levels and accompanying symptoms like nausea. Data regarding changes in accompanying symptoms were not consistent across different published trials.

Combination Therapy Studies

A combination study compared the compound alongside a different CGRP inhibitor to each treatment alone. The research evaluated the overall change in migraine frequency when both compounds were assessed together.

Key Studies & References

1. NICE Guideline NG150: Migraine: assessment and management

Common questions about Оксибрал СР (FAQ)

Q: Is Оксибрал СР considered a serious or high-risk medication?

Official safety information indicates that the most common effects of the medicine are generally mild. However, like all medicines, regulatory documents note rare occurrences of serious adverse events. These events include severe allergic responses and specific cardiovascular irregularities.

Q: Are there any serious side effects associated with Оксибрал СР that I should know about?

The regulatory safety profile documents rare but serious adverse reactions. These reactions include severe allergic responses, such as rash or swelling. Additionally, specific cardiovascular irregularities, such as an irregular heart rhythm (arrhythmia), are noted in safety data.

Q: Can Оксибрал СР affect my ability to drive or operate machinery?

Official safety documents list common effects on the nervous system, such as light-headedness and sleep disturbances. Official information specifies the need for caution, as the risk of drowsiness or impaired alertness is significantly increased if the medicine is used alongside substances that depress the central nervous system.

Q: Does taking Оксибрал СР with food change how it works?

According to the official prescribing information, there are no uniform, explicit instructions provided regarding whether this medicine should be taken specifically with or without food.

Q: Can I take Оксибрал СР if I have kidney or liver issues?

Official regulatory documents specify that the medicine's use is restricted, or that special caution is noted for individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment.

Q: Is it true that Оксибрал СР is a central nervous system medication?

Official documentation and pharmacological studies describe the active ingredient, Vincamine, as exerting focused physiological actions within the central nervous system. It is classified as both a cerebrovasodilator and a nootropic agent.

Q: Can Оксибрал СР interact negatively with common over-the-counter pain relievers?

Official information indicates the medicine may interact with certain types of over-the-counter pain relievers. This interaction could potentially decrease the medicine’s expected therapeutic effectiveness.

Q: Does Оксибрал СР contain lactose or any other common allergens?

Regulatory documents note that the medicine is contraindicated (advised against) in cases of known hypersensitivity to the active substance, Vincamine, or to any of the other non-active ingredients (excipients) that the medicine contains.

Q: What types of heart conditions might prevent someone from using Оксибрал СР?

Official safety constraints highlight the need for specific caution concerning individuals with pre-existing cardiac conditions. This concern particularly relates to conditions involving an irregular heart rhythm, which is medically known as an arrhythmia.

Q: Is there any research that shows Оксибрал СР helps with concentration?

The medicine is classified as a nootropic agent and its general purpose is defined as supporting cerebral function. This includes the defined role of supporting essential cognitive faculties such as memory and attention.

Q: Do regulatory bodies like the FDA or EMA have specific warnings about Оксибрал СР?

Regulatory safety documents detail specific constraints on use. These constraints include contraindication (advice against use) during pregnancy and lactation. They also specify special caution for patients with pre-existing cardiac conditions or those with bleeding disorders.

Q: What is the expected timeline for a course of treatment with Оксибрал СР?

The official administration guidelines state that the duration of a therapeutic course is not predefined by a fixed cycle. Instead, the length of treatment is determined individually by the healthcare professional who is prescribing the medicine.

Q: Are there any known interactions between Оксибрал СР and common supplements (e.g., vitamins)?

Official product labeling does not usually list interactions with specific vitamins or general dietary supplements. However, combining medicines with supplements is subject to general regulatory caution regarding the potential for unintended interactions.

Q: Is it common to feel a bit drowsy when first starting Оксибрал СР?

The official safety profile notes common effects on the nervous system, such as light-headedness and sleep disturbances (insomnia). While drowsiness is not listed as a common effect of the drug alone, the potential for feeling drowsy is significantly increased if it is taken with other central nervous system depressants.

Q: Has Оксибрал СР been studied for uses beyond its primary approved purpose?

The research evidence indicates that studies have examined the compound in relation to conditions that go beyond its primary approved purpose. This has included investigations into migraine frequency and studies of the compound in combination with other therapeutic agents.

Q: Can Оксибрал СР interfere with blood tests or medical procedures?

Regulatory safety constraints highlight the need for special caution concerning individuals with pre-existing bleeding disorders. This caution extends to the peri-operative period, which is the time surrounding a surgical procedure.

Q: Is Оксибрал СР only used for conditions related to blood flow?

Official documents classify the medicine as both a cerebrovasodilator (influencing blood flow) and a nootropic agent, indicating a defined role in supporting neuronal metabolic processes that extends beyond influencing blood flow alone.

Q: Do people who take Оксибрал СР report improvements in memory?

The general purpose of the active ingredient is defined in official literature as supporting cerebral function and promoting cognitive enhancement. This includes supporting essential cognitive faculties such as memory and attention.

Q: What is the potential impact of Оксибрал СР on blood pressure?

The active ingredient is classified as a cerebrovasodilator, which is intended to influence blood vessels and blood flow. Safety documentation notes the need for caution when the medicine is used alongside blood pressure medications, as there is potential for additive effects on blood pressure.

How to Store and Dispose of Оксибрал СР?

The storage and disposal of Оксибрал СР (Vincamine Sustained-Release) must strictly follow official regulatory requirements to maintain the drug's stability and ensure environmental safety.

Storage Conditions

Storage Requirement	Official Condition
Temperature	Store below 25 C (Do not freeze).
Protection	Keep in the original package to protect the contents from moisture and light.
Safety	Must be kept out of the sight and reach of children (Mandatory rule).

Disposal Instructions

Unused or expired medication must not be thrown away with household waste or disposed of via the wastewater system. The product should be returned to a pharmacy or utilized through a local pharmaceutical waste collection scheme, following regional guidelines for proper disposal.